The Net Income for Santhera Pharmaceuticals is detailed below, including the formula and its most recent reported level. This figure is computed using the standard formula applied to filed financial data. The formula breaks the metric into its component accounting inputs. This figure is updated as new financial reports become available. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-41.97 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales. Santhera Pharmaceuticals' Net Income is based on the most recent reporting period. Values are derived from public financial filings. The metric timing follows the most recent available fiscal period. The reporting scope covers the most recently completed fiscal period.
Latest Santhera Pharmaceuticals' Net Loss Growth Pattern
The chart captures Santhera Pharmaceuticals' Net Loss from the earliest available year through the most recent filing. At -39.7 M, the latest figure reflects a 4.76% shift from -37.8 M. Comparing different time windows of Santhera Pharmaceuticals' Net Loss can reveal whether the pace of change is accelerating or slowing.
Understanding the correlations between Santhera Pharmaceuticals' financial accounts, including Net Income, is fundamental to building accurate financial models for Santhera Pharmaceuticals. Because Santhera Pharmaceuticals' key financial indicators are all interdependent within its reporting framework, examining their correlations is more efficient than reviewing each statement independently.
Fiscal trend analysis indicates Accumulated Other Comprehensive Income is set to increase significantly relative to last year. Santhera Pharmaceuticals entered the current period with Accumulated Other Comprehensive Income of -3.79 Million on the books.
At -41.97 Million, Santhera Pharmaceuticals's Net Income is 112.3% lower than the Biotechnology sector and 159.92% lower than the Health Care industry. Compared to all Switzerland stocks, Santhera Pharmaceuticals's reading is 107.35% lower than the aggregate.
Fundamental Drivers Relationships
Sector-based pricing multiples position Santhera Pharmaceuticals within its competitive valuation range. Mapping the correlation between Santhera Pharmaceuticals's fundamental drivers and peer metrics highlights which indicators are most influential for its intrinsic value. More Info.
Santhera Pharmaceuticals Holding is rated below average for net income across the peer group. It is rated below average for return on asset across the peer group . Net Loss is developing negatively compared to historical levels. Year-ago financials show Santhera Pharmaceuticals with Net Loss of -37.78 Million. Comparative pricing ratios evaluate Santhera Pharmaceuticals against peer standards.
Net Income Peer Comparison
Stock peer comparison on Net Income is a widely used and accepted method for evaluating Santhera Pharmaceuticals relative to its direct and indirect competitors. Analyzing Santhera Pharmaceuticals' Net Income against that of similar stocks can help detect undervalued opportunities or identify better portfolio.
Santhera Pharmaceuticals is currently under evaluation for net income across the peer group.
Santhera Pharmaceuticals reports annual revenue of 39.12 M, a profit margin of -133.72%, ROE of -2.88%, debt-to-equity of 196.0. Santhera Pharmaceuticals's financial position is often measured through income generation trends and leverage exposure. Profitability regime consistency underpins valuation stability over time. For this reporting period, Santhera Pharmaceuticals reflects revenue of 39.12 M, EPS loss of 5.38, negative operating margin of 147.6%.
This section for Santhera Pharmaceuticals Holding is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.